Advertisement
U.S. markets open in 3 hours 4 minutes

Barnes Group Inc. (B)

NYSE - NYSE Delayed Price. Currency in USD
36.44-0.13 (-0.36%)
At close: 04:00PM EDT
36.44 0.00 (0.00%)
After hours: 05:48PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close36.57
Open36.51
Bid0.00 x 800
Ask0.00 x 800
Day's Range36.39 - 37.05
52 Week Range18.79 - 43.66
Volume213,991
Avg. Volume340,420
Market Cap1.847B
Beta (5Y Monthly)1.37
PE Ratio (TTM)117.55
EPS (TTM)0.31
Earnings DateApr 25, 2024 - Apr 29, 2024
Forward Dividend & Yield0.64 (1.76%)
Ex-Dividend DateFeb 21, 2024
1y Target Est37.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-32% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for B

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Barnes Group, Inc.
    B: Raising target price to $40.00BARNES GROUP INC has an Investment Rating of HOLD; a target price of $40.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • PR Newswire

    BioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conference

    BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi, the world's first fully approved disease-modifying treatment for Alzheimer's disease. According to Eisai's simulation, Leqembi sales will reach JPY 290 billion for their financial year (FY) 2026, which ends in March 2027 and JPY 1.6 trillion in FY2032.

  • Business Wire

    Barnes Announces Update to Board of Directors

    BRISTOL, Conn., March 05, 2024--Barnes Group Inc. (NYSE: B), a global provider of highly engineered products, differentiated industrial technologies, and innovative solutions, today announced the planned retirements of Chairman Thomas O. Barnes and Lead Independent Director Mylle H. Mangum, consistent with the Company’s corporate governance retirement policy, effective at the Company’s Annual Meeting of Stockholders in May 2024. Mr. Barnes will become Chairman Emeritus and continue to lead the B

  • Simply Wall St.

    Barnes Group Full Year 2023 Earnings: EPS Beats Expectations

    Barnes Group ( NYSE:B ) Full Year 2023 Results Key Financial Results Revenue: US$1.45b (up 15% from FY 2022). Net...